Research dossier
Clinical research on Vitamin B3
5 trials reviewed across 5 indications.
Strongest evidence
Pellagra prevention and deficiency repletion
Mechanism
Niacin is required to make NAD and NADP — coenzymes used in over 400 enzymatic reactions including energy production, DNA repair, and cellular signaling. Without enough niacin, the entire oxidative metabolism fails.
Pellagra responds to niacin as reliably as scurvy responds to vitamin C. The deficiency disease ('three Ds' — dermatitis, diarrhea, dementia) was a public health crisis in the early 20th century US South before niacin fortification of grain. In modern populations, deficiency is rare except in alcohol use disorder, malabsorption, or specific drug regimens.
If you're not deficient and you eat ordinary food, you have plenty of niacin. The RDA is 14–16 mg/day and most diets supply far more from meat, fish, peanuts, and fortified grain.
Trials cited
Niacin for pellagra (deficiency disease)
positive · Observational
WHO and historical clinical evidence; reviewed in StatPearlsNiacin replacement in pellagra reverses the classic dermatitis, diarrhea, and dementia within weeks. The clinical evidence here predates the modern RCT era — it's as well-established as scurvy responding to vitamin C. Nicotinamide is preferred over nicotinic acid for treatment because it lacks the flush and the cholesterol effects.
Skin (pellagra dermatitis, topical niacinamide)
Mechanism
Niacin deficiency causes the photosensitive dermatitis of pellagra. Topical niacinamide (separately from oral supplementation) has its own evidence base in inflammatory acne and barrier function — but that is a topical-product story, not a systemic-supplement story.
Oral niacin supplementation in non-deficient adults does not have strong skin-improvement evidence. Topical niacinamide in skincare is a different category and is reasonably well-studied for acne and barrier support. Don't confuse the two.
If your skin issue is pellagra-related dermatitis, oral niacin reverses it. Otherwise, look at topical niacinamide formulations for skin claims.
Cholesterol and cardiovascular disease
Mechanism
Pharmacologic doses of nicotinic acid (1.5–3 g/day) bind GPR109A receptors on adipocytes, reducing free fatty acid release and downstream VLDL/LDL production. Niacin raises HDL and lowers triglycerides more than any other lipid drug.
Here's the brutally honest version: niacin used to be a cholesterol drug. The Coronary Drug Project (pre-statin era) showed it reduced heart attacks. Then statins arrived. Then AIM-HIGH (2011) and HPS2-THRIVE (2014) tested whether adding niacin to a statin produced extra benefit — both said no, and HPS2-THRIVE showed extra harm including a 33% increase in new diabetes. The FDA pulled the indication. Don't take high-dose niacin for cardiovascular prevention.
The lipid effects (HDL up, triglycerides down) are real. The clinical-outcome benefit on top of a statin is not. If you have severely elevated triglycerides or are statin-intolerant, this is a discussion with a lipidologist, not a do-it-yourself supplement decision.
Coronary Drug Project — long-term niacin mortality
positive · RCT
Canner et al., 1986, Journal of the American College of Cardiologyn=8341The original Coronary Drug Project (1966–1975) showed niacin modestly reduced recurrent non-fatal heart attacks. The Canner follow-up published in 1986 showed an 11% reduction in all-cause mortality at 15 years. Conducted entirely in the pre-statin era — the foundational evidence for niacin's reputation as a cardiovascular drug.
Pre-statin era. The benefit signal disappeared once statins became standard care, as shown by AIM-HIGH and HPS2-THRIVE.
AIM-HIGH — niacin added to statin therapy
negative · RCT
AIM-HIGH Investigators, 2011, NEJMn=34143,414 statin-treated patients with established cardiovascular disease got extended-release niacin or placebo on top of their statin. Niacin raised HDL and lowered triglycerides — and produced exactly zero reduction in cardiovascular events. The trial was stopped early for futility. A higher rate of ischemic stroke in the niacin arm raised additional concern.
HPS2-THRIVE — extended-release niacin/laropiprant
negative · RCT
HPS2-THRIVE Collaborative Group, 2014, NEJMn=25673The largest niacin-cardiovascular trial ever done. 25,673 high-risk patients on statins added niacin or placebo for nearly 4 years. Major vascular events: no reduction. Harms increased meaningfully — new diabetes diagnoses up by one-third (about 13 extra cases per 1,000 treated), plus more bleeding, infections, and gout. Closed the door on niacin as add-on cardiovascular therapy.
Energy and fatigue
Mechanism
NAD is the central electron carrier in cellular energy metabolism. Every step of glycolysis, the Krebs cycle, and oxidative phosphorylation depends on NAD/NADH cycling.
The biochemistry is unimpeachable — without niacin, cellular energy production collapses. The clinical claim that 'extra niacin gives you more energy in the absence of deficiency' is not supported by trial evidence. The current NAD-precursor wave (nicotinamide riboside, nicotinamide mononucleotide) is studied with a different mechanism in mind and is not the same molecule as supplemental niacin.
Repletion in genuine deficiency restores normal energy. Mega-dosing past sufficiency does not stack additional fatigue benefit and brings real side effects.
Glucose metabolism
Mechanism
High-dose niacin worsens insulin sensitivity by increasing free fatty acid flux from impaired adipocyte storage. The mechanism is the inverse of niacin's lipid-lowering effect.
High-dose niacin makes blood sugar worse. HPS2-THRIVE confirmed this in the largest dataset — a 33% increase in new diabetes diagnoses on niacin vs placebo. This is the opposite of a metabolic benefit. Anyone with prediabetes or type 2 diabetes should avoid high-dose niacin.
Listed here as a negative-effect entry, not a benefit. The honest read: high-dose niacin is a glucose-control liability, not a metabolic aid.
HPS2-THRIVE — extended-release niacin/laropiprant
negative · RCT
HPS2-THRIVE Collaborative Group, 2014, NEJMn=25673The largest niacin-cardiovascular trial ever done. 25,673 high-risk patients on statins added niacin or placebo for nearly 4 years. Major vascular events: no reduction. Harms increased meaningfully — new diabetes diagnoses up by one-third (about 13 extra cases per 1,000 treated), plus more bleeding, infections, and gout. Closed the door on niacin as add-on cardiovascular therapy.
Honest-evidence ledger — 1 trial that didn’t move the needle
Surfacing failed trials alongside the positive evidence. Leaving them out would be marketing, not science.
Lange — B vitamins after coronary stenting
negative · RCT
Lange et al., 2004, NEJMn=636636 post-stent patients took folic acid + B12 + B6 or placebo for 6 months. The B-vitamin group had higher restenosis rates (HR 1.34, p=0.05). One of several signals that homocysteine-lowering does not protect the cardiovascular system and may harm in some contexts. Included here because B6 was a co-intervention.
Combined intervention — cannot isolate which B vitamin drove the signal. Subsequent niacin trials (AIM-HIGH, HPS2-THRIVE) established that the niacin-on-statin approach also fails.
6 forms of Vitamin B3 compared
Nicotinic acid (niacin)
Well absorbed
Best forLipid effects (raises HDL, lowers triglycerides) and pellagra repletionThe form that causes the famous niacin flush — facial redness, warmth, tingling, itching for 15–30 minutes after dosing, mediated by prostaglandin D2. The flush is uncomfortable but harmless. This is the form used in the cardiovascular trials. AIM-HIGH and HPS2-THRIVE used extended-release versions specifically to reduce flushing.
Niacinamide (nicotinamide)
Well absorbed
Best forPellagra repletion, NAD precursor, B-complex formulas, topical skincareNo flush. No cholesterol effect either — different downstream pharmacology than nicotinic acid. The standard form for treating pellagra and the form usually found in B-complex supplements. If you don't want flushing and don't need lipid effects, this is the form.
Inositol hexanicotinate (IHN)
Poor and inconsistent
Best forMarketed as 'no-flush niacin' for cholesterolSold as a flush-free way to get niacin's cholesterol effects. The actual evidence: it doesn't reliably hydrolyze to free nicotinic acid in the body, so it doesn't deliver the lipid effects. If you want the lipid effects, use real nicotinic acid (with the flush). If you don't, use niacinamide. Inositol hexanicotinate is a worst-of-both-worlds form.
Niaspan®
Extended-release nicotinic acid
Slow-release, designed to reduce flushing
Best forPrescription lipid managementThe form used in HPS2-THRIVE and AIM-HIGH. Reduces flush relative to immediate-release nicotinic acid but carries higher hepatotoxicity risk at gram-level doses. After the failed cardiovascular trials, FDA-approved indications were narrowed.
Niagen®
Nicotinamide riboside (NR)
Well absorbed; raises blood NAD+ levels measurably
Best forNAD+ precursor — studied for aging, metabolism, mitochondrial functionA separate molecule from typical niacin supplements, sharing the upstream NAD+ pathway but marketed under a longevity/anti-aging frame. Trials show NAD+ levels rise; clinical-outcome data is still early. Don't confuse this with conventional niacin or treat it as interchangeable.
Nicotinamide mononucleotide (NMN)
Debated — some evidence of NAD+ elevation
Best forNAD+ precursor, longevity-focusedLike NR, marketed in the longevity space. Evidence base is younger and weaker than NR. Treat human-outcome claims with skepticism.
Are you deficient? Symptoms, risk groups, lab tests
Pellagra (frank niacin deficiency) is rare in countries with grain fortification. It persists in adults with alcohol use disorder, severe malabsorption, certain drug regimens (isoniazid for tuberculosis), and in unfortified populations with corn-dominant diets that lack tryptophan.
Common symptoms
- Photosensitive dermatitis on sun-exposed skin (the classic 'pellagra collar')
- Diarrhea and gastrointestinal inflammation
- Cognitive changes — confusion, memory loss, dementia in severe cases
- Fatigue and weakness
- Loss of appetite
- Sore, red tongue (glossitis)
- Mouth ulcers
- Mood changes including irritability or depression
- Headache
Who is at risk
Adults with alcohol use disorder
Alcohol impairs niacin absorption and conversion of tryptophan to niacin. Pellagra was historically associated with chronic alcoholism.
e.g. isoniazid
Patients on isoniazid (tuberculosis therapy)
Isoniazid interferes with vitamin B6, which is required for tryptophan-to-niacin conversion. Isoniazid-induced pellagra is well-documented.
Patients with carcinoid syndrome
Carcinoid tumors divert tryptophan toward serotonin synthesis, leaving less available for niacin synthesis.
Adults with severe malabsorption
Crohn's disease, celiac disease, post-bariatric surgery, and chronic diarrhea can all reduce niacin absorption.
Populations with corn-dominant diets without nixtamalization
Niacin in untreated corn is bound and biologically unavailable. Traditional Mesoamerican lime treatment (nixtamalization) liberates niacin — populations that adopted corn without this processing developed pellagra.
Lab markers
Urinary niacin metabolites (N1-methyl-nicotinamide)
Niacin status is rarely measured in routine clinical practice. Diagnosis is typically made on the clinical picture (the three Ds) plus response to repletion.
- Deficiency (low excretion)
- <0.8 mg/day
Side effects and drug interactions
Side effects
Flushing
Common · Begins at ~50 mg of immediate-release nicotinic acid; near-universal at gram doses
Facial redness, warmth, tingling, and sometimes itching for 15–30 minutes after a dose of nicotinic acid. Mediated by prostaglandin D2. Uncomfortable but harmless. Niacinamide and inositol hexanicotinate do not cause flushing.
Worse with:nicotinic acid, extended-release niacin
Gentler:niacinamide
Liver toxicity
Severe · Above 1 g/day, especially with sustained-release formulations
Elevated liver enzymes and rare cases of acute liver failure, particularly with sustained-release nicotinic acid at gram-level doses. The risk is form-specific and dose-dependent.
Worse with:extended-release niacin, nicotinic acid
Hyperglycemia and new-onset diabetes
Common · Pharmacologic doses (1.5–2 g/day)
High-dose niacin worsens insulin sensitivity. HPS2-THRIVE showed a 33% increase in new diabetes diagnoses over 4 years.
Worse with:extended-release niacin, nicotinic acid
Hyperuricemia and gout
Uncommon · Pharmacologic doses
Niacin reduces uric acid clearance. Can precipitate gout flares in susceptible individuals.
GI upset
Common
Nausea, abdominal pain, vomiting, diarrhea — particularly at high doses or on an empty stomach.
Increased bleeding risk
Uncommon · Pharmacologic doses
Reported in HPS2-THRIVE. Mechanism uncertain.
Infections
Uncommon
HPS2-THRIVE showed increased serious infection rates on niacin/laropiprant. Mechanism unclear.
Drug interactions
Combined-effect risk
statins (simvastatin, atorvastatin, rosuvastatin)Statins plus high-dose niacin increase risk of myopathy and rhabdomyolysis. The combination is rarely justified given the failed cardiovascular outcomes.
Don't combine high-dose niacin with statins outside specialist supervision. AIM-HIGH and HPS2-THRIVE established no benefit from this combination.
Additive effect
antihypertensivesalpha-blockersNiacin's vasodilatory flush can amplify hypotension when stacked with blood pressure medications.
Watch for orthostatic symptoms when starting niacin in adults on antihypertensives.
Reduces nutrient status
allopurinolNiacin raises uric acid, working against allopurinol's gout-prevention effect.
Avoid high-dose niacin in adults with gout history.
Other
diabetic medications (metformin, insulin, sulfonylureas)Niacin worsens glycemic control and may require dose adjustment of diabetes medications.
Adults on diabetes therapy should avoid high-dose niacin or coordinate closely with their prescriber.
Other critical caveats
- Two large randomized trials (AIM-HIGH 2011 in 3,414 patients, HPS2-THRIVE 2014 in 25,673 patients) tested niacin added to statin therapy and both found zero cardiovascular benefit plus harms. New-onset diabetes increased by one-third in HPS2-THRIVE. Don't take high-dose niacin for cardiovascular prevention.
- High-dose niacin can damage the liver, raise blood sugar, raise uric acid, and trigger gout. The pharmacologic doses (1.5–2 g/day) used for lipid effects are not casual supplements — they're drug-level doses that need monitoring.
- Inositol hexanicotinate ('no-flush niacin') marketing claims that it delivers lipid effects without flushing. It doesn't reliably deliver the lipid effects either, because it doesn't hydrolyze well to active nicotinic acid. If you want lipid effects, you have to accept the flush.
- Niacinamide and nicotinic acid are not interchangeable above the RDA. Niacinamide doesn't flush but also doesn't have the cholesterol effects. Most B-complex supplements use niacinamide because it's gentler — that's fine for repletion, but won't reproduce the lipid pharmacology of nicotinic acid.
Frequently asked
Why does niacin make me flush?
The flush is a prostaglandin-D2-mediated vasodilation triggered by nicotinic acid binding to GPR109A receptors. It causes facial redness, warmth, tingling, and sometimes itching for 15–30 minutes after a dose. It's harmless but uncomfortable. Aspirin pre-dosing reduces it. Niacinamide doesn't cause it because it doesn't bind the receptor — but it also doesn't produce the cholesterol effects.Should I take niacin for my cholesterol?
Probably not. Two large modern trials (AIM-HIGH, HPS2-THRIVE) tested niacin added to a statin and both failed — no cardiovascular benefit, plus extra harm including a 33% increase in new diabetes. The FDA narrowed the lipid indications. If you have severely elevated triglycerides, a specific lipid disorder, or you can't tolerate statins, niacin is a discussion to have with a cardiologist or lipidologist — not a do-it-yourself supplement decision.How much niacin do I actually need?
The RDA is 14 mg/day for women and 16 mg/day for men, easily met by ordinary diets containing meat, fish, peanuts, or fortified grain. The supplemental upper limit is 35 mg/day to avoid flushing in healthy adults. Pharmacologic doses for lipid effects start at 1,500 mg/day — that's drug territory, not supplement territory.What's the difference between niacin, niacinamide, and nicotinic acid?
'Niacin' is an umbrella term covering both nicotinic acid (the form that flushes and lowers cholesterol) and niacinamide / nicotinamide (the form that doesn't flush and doesn't affect cholesterol). They both correct deficiency. Above the RDA, they have different downstream effects — only nicotinic acid produces the lipid pharmacology. Most B-complex products use niacinamide because it's gentler. Most cardiovascular trials used nicotinic acid (or its extended-release form).Is niacinamide safe at high doses?
Niacinamide is gentler than nicotinic acid — no flush, no liver hits at moderate doses. But sustained gram-level doses can still cause GI upset and have been associated with rare hepatotoxicity. Topical niacinamide in skincare is a separate story with its own evidence base for acne and barrier function.
References
- 01NIH Office of Dietary Supplements — Niacin Health Professional Fact Sheet
- 02StatPearls — Niacin Deficiency (NCBI Bookshelf)
- 03AIM-HIGH and HPS2-THRIVE summaries — American College of Cardiology
Last reviewed2026-05-07